Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:55:51.318Z.
Calculation as of: 2026-10-06T21:55:51.318Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69328368594ca01c79a1d7ac3810be200bc4ff9949d0867bb2c2a7ab20a5f204
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Anavex Life Sciences Corp.
Market Cap
$148.27M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.64M
Operating Cash Flow Yield
N/A
TTM Avg
19.26%
3Y Avg
12.33%
5Y Avg
11.77%
Market Cap
$148.73M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.36M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.62M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.28M
Operating Cash Flow Yield
N/A
TTM Avg
4.20%
3Y Avg
4.20%
5Y Avg
4.20%
Market Cap
$146.27M
Operating Cash Flow Yield
86.09%
TTM Avg
20.54%
3Y Avg
20.54%
5Y Avg
20.54%
Market Cap
$151.01M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.84M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anavex Life Sciences Corp. (AVXL) | $148.27M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | N/A | 19.26% | 12.33% | 11.77% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $146.28M | N/A | 4.20% | 4.20% | 4.20% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 86.09% | 20.54% | 20.54% | 20.54% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | N/A | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $152.72M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
